9 Meters Biopharma, Inc. (NMTRQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0001 (-50.00%)
Aug 8, 2025, 3:48 PM EDT
-50.00%
Market Cap1.45K
Revenue (ttm)n/a
Net Income (ttm)-46.28M
Shares Out14.46M
EPS (ttm)-3.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume200
Average Volume3,291
Openn/a
Previous Close0.0002
Day's Rangen/a
52-Week Rangen/a
Beta12.89
RSI59.39
Earnings Daten/a

About 9 Meters Biopharma

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to preven... [Read more]

Industry Biotechnology
Sector Healthcare
Employees 10
Stock Exchange OTCMKTS
Ticker Symbol NMTRQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.